A traditional Chinese medicine for treating thrombocytopenic purpura

Abstract

The invention relates to a traditional Chinese medicine for treating thrombocytopenic purpura. The traditional Chinese medicine comprises the following components in parts by weight: 150 to 170g of cornus officinalis, 110 to 130g of rumex japonicas, 90 to 110g of pseudo-ginseng, 110 to 130g of astragalus membranaceus, 110 to 130g of angelica sinensis, 110 to 130g of fructus lycii, 90 to 110g of glossy privet fruit, 90 to 110g of herba ecliptae, 90 to 110g of caulis spatholobi, 18 to 22g of american ginseng, and 78 to 82g of callicarpa bodinieri. Other components in parts by weight also can be added to the traditional Chinese medicine based on the components as follows: 6 to 15g of fructus ziziphi jujubae, 6 to 9g of rubia cordifolia and 5 to 9g of cattail pollen. Under the coordination of all the components, the traditional Chinese medicine has the effects of clearing heat and cooling blood, replenishing blood and tonifying Qi, dispersing blood stasis and stopping bleeding and treating the deficiency of both blood and Qi and stagnation of heat stasis leading to thrombocytopenic purpura, such as skin petechiae, ecchymosis, black red, thrombocytopenia, hemorrhage, fever, polydipsia, palpitation, insomnia, vertigo, lack of energy, pain in joints, waist and abdomen, dark urine with burning sensation and constipation. The result of clinical application shows that the traditional Chinese medicine is remarkable in therapeutic effect and low in toxic and side effects and has a good application prospect.

Description

technical field [0001] The invention relates to a traditional Chinese medicine for treating thrombocytopenic purpura. Background technique [0002] Thrombocytopenic purpura is a common clinical bleeding disorder characterized by spontaneous bleeding, thrombocytopenia, prolonged bleeding time and poor clot contraction. The development and maturation of megakaryocytes in BM is inhibited. Recent research results show that the pathogenesis of the disease is related to immunity. In cases of thrombocytopenia without a specific etiology, about 85% of patients have IgG antibodies in serum or platelets. [0003] The characteristics of thrombocytopenic purpura: the lifespan of platelets is obviously shortened, anti-platelet autoantibodies appear, bone marrow megakaryocytes increase, maturation disorder, and platelet renewal accelerate. Clinically, it can be divided into two types: acute and chronic. The former is usually self-limiting, mostly in children, while the latter is more com...

AI Technical Summary

Problems solved by technology

Hormone drugs can cause certain damage to human bone marrow, gamma globulin is expensive, and its effect and curative effect are short